Oxygen Biotech is developing BAZE-X1, an all-in-one treatment for the patients with severe COVID-19 (SARS-CoV-2) / ARDS & post-COVID Syndrome (PCS).
We follow on from the R&D organization BIOCEV — a joint project of six institutes of the Academy of Sciences of the Czech Republic and two faculties of Charles University in Prague (Faculty of Science and 1st Faculty of Medicine).
BAZE-X1 is a patented drug that has „dual-mode“ of action:
◼︎ antiviral
◼︎ immunomodulatory
Our team consists of leading Czech scientists, clinicians, and internationally recognized specialists both in the European Union (EU) and the United States of America (USA).
Company Details
- Employees
- 4
- Founded
- -
- Address
- Italská 67, Churchill I.,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://oxygenbiotech.com
- Keywords
- IT Consulting.
- HQ
- Praha 2, Praha
Oxygen Biotech Questions
Oxygen Biotech's website is https://oxygenbiotech.com
Oxygen Biotech's LinkedIn profile is https://www.linkedin.com/company/oxygenbiotech
Oxygen Biotech has
4 employees.
View email and phone details for 4
employees at Oxygen Biotech.
Oxygen Biotech's industry is
Pharmaceutical Manufacturing
Oxygen Biotech's top competitors are
Virtual Labs,
Oaks Consulting S.r.o.,
Virtual Lab,
Royax S.r.o.,
Vpv Xport,
Neurona Lab,
Carebot,
Vr Vitalis®,
Visioncraft,
Legend Has It Studios.
Oxygen Biotech's categories are Pharmaceutical Manufacturing
Oxygen Biotech's founding year is 2020
